Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies

A highly concentrated (20%) immunoglobulin (Ig)G preparation for subcutaneous administration (IGSC 20%), would offer a new option for antibody replacement therapy in patients with primary immunodeficiency diseases (PIDD). The efficacy, safety, tolerability and pharmacokinetics of IGSC 20% were evalu...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Exp Immunol
Autori principali: Borte, M., Kriván, G., Derfalvi, B., Maródi, L., Harrer, T., Jolles, S., Bourgeois, C., Engl, W., Leibl, H., McCoy, B., Gelmont, D., Yel, L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2016
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5167020/
https://ncbi.nlm.nih.gov/pubmed/27613250
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.12866
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi